Chimeric Therapeutics Ltd (CHM) - Total Liabilities

Latest as of June 2025: AU$19.60 Million AUD ≈ $13.87 Million USD

Based on the latest financial reports, Chimeric Therapeutics Ltd (CHM) has total liabilities worth AU$19.60 Million AUD (≈ $13.87 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Chimeric Therapeutics Ltd generate cash to assess how effectively this company generates cash.

Chimeric Therapeutics Ltd - Total Liabilities Trend (2020–2025)

This chart illustrates how Chimeric Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Chimeric Therapeutics Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Chimeric Therapeutics Ltd Competitors by Total Liabilities

The table below lists competitors of Chimeric Therapeutics Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Semacom Integrated Tbk PT JK:SEMA	Indonesia	Rp118.33 Billion
Vanadium Resources Ltd AU:VR8	Australia	AU$536.13K
Zeta Network Group NASDAQ:ZNB	USA	$12.50 Million
Turbon AG F:TUR	Germany	€15.83 Million
Touchwood Entertainment Limited NSE:TOUCHWOOD	India	Rs133.18 Million
Ease2pay NV AS:EAS2P	Netherlands	€2.36 Million
Urban Logistics Reit PLC LSE:SHED	UK	GBX441.04 Million
Domino’s Pizza Group PLC LSE:DOM	UK	GBX678.70 Million

Liability Composition Analysis (2020–2025)

This chart breaks down Chimeric Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Chimeric Therapeutics Ltd (CHM) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.72	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	0.39	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	9.92	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.91	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Chimeric Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Chimeric Therapeutics Ltd (2020–2025)

The table below shows the annual total liabilities of Chimeric Therapeutics Ltd from 2020 to 2025.

Year	Total Liabilities	Change
2025-06-30	AU$19.60 Million ≈ $13.87 Million	+53.06%
2024-06-30	AU$12.80 Million ≈ $9.06 Million	-23.40%
2023-06-30	AU$16.71 Million ≈ $11.83 Million	+82.21%
2022-06-30	AU$9.17 Million ≈ $6.49 Million	-19.35%
2021-06-30	AU$11.37 Million ≈ $8.05 Million	+17670.20%
2020-06-30	AU$64.01K ≈ $45.29K	--

About Chimeric Therapeutics Ltd

AU:CHM Australia Biotechnology

Market Cap

$484.61 Million

AU$684.90 Million AUD

Market Cap Rank

#27174 Global

#1375 in Australia

Share Price

AU$0.16

Change (1 day)

-3.13%

52-Week Range

AU$0.00 - AU$0.21

All Time High

AU$0.39